摘要
目的了解大肠埃希菌和肺炎克雷伯菌产超广谱β-内酰胺酶(ESBLs)的耐药性,为临床合理使用抗菌药物提供依据。方法采用法国生物梅里埃公司ATB细菌鉴定仪对ESBLs菌进行检测,药敏试验用K-B纸片法,根据2005年美国临床实验室标准化委员会(NCCLS)标准判断结果,应用WHONET5软件对临床分离细菌的药敏结果进行数据统计分析。结果检出产ESBLs细菌431株,检出率42.05%,其中大肠埃希菌330株,检出率49.03%,肺炎克雷伯菌101株,检出率28.69%;产ESBLs对碳青酶烯类(美罗培南、亚胺培南)、头孢西丁及β-内酰胺酶抑制剂复合物、阿米卡星耐药性较低在0～28.4%,其余抗菌药物都产生较高的耐药性。结论重视产ESBLs细菌检测,根据药敏试验结果合理用药,碳青酶烯类、头孢西丁及β-内酰胺酶抑制剂复合物、阿米卡星是目前治疗ESBLs细菌有效抗菌药物。
OBJECTIVE To investigate the characteristics about drug resistance of extended-spectrum β-1actamases （ESBLs）-producing bacteria for the guidance of clinical rational use of antibiotics. METHODS To detect ESBLs by ATB microbiological system. We used Kirby-Bauer（K-B）test for antibiotics susceptibility test. The results were evaluated based on National Committee for Clinical Laboratory Standards （NCCLS） of the USA in 2005. The data were analyzed by using WHONET-5 software. RESULTS Among the isolated 431 strains of ESBLs-producing bacteria （42.05%）, 330 strains were of Escherichia coli （49.03%）, and 101 strains of Klebsiella pneumoniae （28.69%） ; the resistant rate of ESBLs-producing bacteria to carbapenem （meropemem, imipenem-cilastatin）, cefoxitin, complex antibiotics containing β-lactamases inhibitor, and amikacin was relatively less（0-28.4%）, the resistant rate to other antimicrobial drugs was higher. CONCLUSIONS It is very important to determine ESBLs- producing bacteria. Correctly selecting antimicrobial drugs for infection treatment is conducted according to the results of susceptibility tests. The effective antimicrobial drugs to infections caused by ESBLs-producing bacteria are carbapenem, cefoxitin, complex antibiotics containing β-1actamases inhibitor and amikacin.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2007年第7期878-880,共3页
Chinese Journal of Nosocomiology
关键词
超广谱Β-内酰胺酶
抗菌药物
耐药性
分析
Extended-spectrum β-1actamases（ESBLs）
Antimicrobial drugs
Resistance
Analysis
